Literature DB >> 2404576

Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma.

V E Quarmby1, W C Beckman, D B Cooke, D B Lubahn, D R Joseph, E M Wilson, F S French.   

Abstract

The Dunning R-3327 rat prostatic adenocarcinoma and its sublines have been developed as a model system to study prostate tumor progression. We have used this system to study the changes in androgen receptor (AR) and AR mRNA expression which occur during tumor progression from androgen dependent to androgen independent growth. Dorsal prostate and all tumor sublines contained a 10-kilobase AR mRNA on Northern blot analysis. The levels of AR mRNA in each subline compared to dorsal prostate (100%) were: H (75%) greater than G (48%) greater than HI (25%) greater than HI-F = AT-1 = AT-3 = MAT-Lu = MAT-Ly-Lu = less than 5%. Immunocytochemistry showed AR predominantly in acinar epithelial cells of dorsal prostate and the androgen sensitive H subline. In the H subline, both acinar epithelial cells and locally invasive adenocarcinoma cells within the stroma showed positive immunostaining. The androgen responsive, anaplastic G subline also showed strong positive immunostaining. The androgen resistant AT-1 and MAT-Lu sublines lacked immunostaining for the AR. Steroid autoradiography revealed a similar cellular distribution of AR. These data suggest that in the Dunning system the loss of androgen binding and responsiveness is primarily due to selective changes in gene expression and not to gene rearrangements or posttranscriptional or translational modification of the AR mRNA or protein.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2404576

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells.

Authors:  Masashi Kobayashi; Yanqing Huang; Chengliu Jin; Yongde Luo; Tetsuji Okamoto; Fen Wang; Wallace L McKeehan
Journal:  Prostate       Date:  2011-03-28       Impact factor: 4.104

2.  Hormone-refractory prostate cancer: new horizons.

Authors:  Daniel P Petrylak
Journal:  Rev Urol       Date:  2003

Review 3.  Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy.

Authors:  Z Culig; A Hobisch; A Hittmair; M V Cronauer; C Radmayr; G Bartsch; H Klocker
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

4.  1-dehydro-melengestrol acetate inhibits the growth and protein kinase C activity of androgen-independent Dunning rat prostatic tumors.

Authors:  M J Battistone; G M Padilla; V Petrow
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Lung microenvironment promotes the metastasis of human hepatocellular carcinoma cells to the lungs.

Authors:  Yun Jin; Junhua Ai; Jun Shi
Journal:  Int J Clin Exp Med       Date:  2015-06-15

6.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.

Authors:  J A Ruizeveld de Winter; P J Janssen; H M Sleddens; M C Verleun-Mooijman; J Trapman; A O Brinkmann; A B Santerse; F H Schröder; T H van der Kwast
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

7.  Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up.

Authors:  L P Pertschuk; R J Macchia; J G Feldman; K A Brady; M Levine; D S Kim; K B Eisenberg; E Rainford; G S Prins; G L Greene
Journal:  Ann Surg Oncol       Date:  1994-11       Impact factor: 5.344

8.  From prostate to bone: key players in prostate cancer bone metastasis.

Authors:  Megan N Thobe; Robert J Clark; Russell O Bainer; Sandip M Prasad; Carrie W Rinker-Schaeffer
Journal:  Cancers (Basel)       Date:  2011       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.